On September 21, Moderna, Inc. rose 4.67% in regular trading, trading at $163.0765 per share, with turnover of $141 million, extending a recent rally that has seen the stock more than double over the past month.

The sustained upside is primarily driven by the landmark Phase 3 INTerpath-001 trial results for intismeran autogene, a personalized mRNA cancer vaccine co-developed with Merck. The trial demonstrated positive outcomes on both recurrence-free survival and distant metastasis-free survival endpoints, with no new safety concerns identified. This marks the first individualized mRNA cancer therapy to show efficacy in a randomized Phase 3 trial, prompting a broad reassessment of mRNA technology's commercial potential in oncology.

Multiple institutions have recently raised their price targets. Argus Research upgraded the stock to Buy with a $180 target, while Barclays lifted its target from $48 to $125 and Berenberg raised its target to $100 from $45. UBS, maintaining a $150 target, highlighted three near-term data readouts on individualized neoantigen therapies as further potential catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)